Formularies, costs, and quality of care: Formulary restrictions are not the answer, especially for epilepsy

Neurology: Clinical Practice

Volumn 3, Issue 1, 2013, Pages 71-74

  Labiner, David M ^a   Drake, Kendra W ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE;

ADD ON THERAPY; ARTICLE; CAUSE OF DEATH; DEPRESSION; DRUG COST; DRUG EFFICACY; DRUG FORMULARY; DRUG MECHANISM; DRUG TOLERANCE; EMERGENCY TREATMENT; EPILEPSY; GOLD STANDARD; HEALTH CARE QUALITY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; MONOTHERAPY; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEIZURE; SIDE EFFECT; TERATOGENESIS; UNSPECIFIED SIDE EFFECT;

EID: 84875829031     PISSN: 21630402     EISSN: 21630933     Source Type: Journal    
DOI: 10.1212/CPJ.0b013e318283ff65     Document Type: Article

References (5)

1. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;345:314-319.
2. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006;47:1094-1120.
3. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy. Neurology 2004;62:1261-1273.
4. Talati R, Scholle JM, Phung OJ, et al. Effectiveness and Safety of Antiepiltpic Medications in Patients with Epilepsy: Comparative Effectiveness Review No. 40. AHRQ Publication No. 11(12)-EHC082- EF. Rockville, MD: Agency for Healthcare Research and Quality; 2011. Available at: www.effectivehealthcare. ahrq.gov/reports/final.cfm.
5. Labiner DM, Paradis PE, Duh MS, et al. Generic antiepileptic drugs and associated medical resource utilization in the United States. Neurology 2010;74:1566-1574.